Amendment “New nomenclature for MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)” to the S2k guideline “Non-alcoholic fatty liver disease” (v.2.0/April 2022) of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)

Table of contents		Page
List of abbreviations		2066
List of tables		2066
List of figures		2066
1	Information on the amendment	2066
1.1	Publisher	2066
1.2	Leading professional association	2066
1.3	Scope and purpose	2066
1.4	Goal orientation of the amendment	2067
1.5	Service area	2067
1.6	User target group/addressees	2067
1.7	Composition of the guideline group: participation of interest groups	2067
1.8	Representativeness of the guideline group: participating professional associations/institutions	2067
1.9	Representativeness of the guideline group: participation of patient representatives	2068
2	Methodological approach	2068
2.1	Schedule	2069
3	External review and approval	2069
3.1	Adoption by the boards of the publishing professional societies/organizations	2069
3.2	Editorial independence and financing of the guideline	2069
3.3	Disclosure of and dealing with conflicts of interest	2069
4	Dissemination and implementation	2069
4.1	Concept for dissemination and implementation	2069
4.2	Validity period and updating procedure	2069
5	Editorial note	2069
5.1	Gender-neutral wording	2069
5.2	Participatory decision-making	2069
5.3	Special note	2070
1 Amendment – New nomenclature for MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) [consensus]		2070
References		2074

List of abbreviations

AASLD: American Association for the Study of Liver Disease

ALD: Alcohol-associated liver disease (ALD)

ALEH: Asociación Latinoamericana para el Estudio del Hígado

EASL: European Association for the Study of the Liver

EMA: European Medicines Agency

FDA: Food and Drug Administration (US-American)

MAFLD: Metabolic Dysfunction-Associated Fatty Liver Disease

MASH: Metabolic Dysfunction-Associated Steatohepatitis

MASLD: Metabolic Dysfunction-Associated Steatotic Liver Disease

MetALD: Metabolic Dysfunction-Associated Steatotic Liver Disease with moderate alcohol intake

NAFL: Non-alcoholic fatty liver

NAFLD: Non-alcoholic fatty liver disease

NASH: Non-alcoholic steatohepatitis

SLD: Steatotic liver disease

Publication History

Article published online:
06 December 2024

• References

• 1 Rinella ME, Lazarus JV, Ratziu V. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; 79: 1542-1556
• 2 Ludwig J, Viggiano TR, McGill DB. et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438
• 3 Geier A, Tiniakos D, Denk H. et al. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021; 70: 1570-1579
• 4 Roeb E, Canbay A, Bantel H. et al. Updated S2k guideline non-alcoholic fatty liver disease of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF registry number: 021-025. Z Gastroenterol 2022; 60: 1346-1421
• 5 Roeb E, Steffen HM, Bantel H. et al. S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol 2015; 53: 668-723
• 6 Eslam M, Newsome PN, Sarin SK. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020; 73: 202-209
• 7 Loomba R, Ratziu V, Harrison SA. Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. Gastroenterology 2022; 162: 680-688
• 8 Israelsen M, Torp N, Johansen S. et al. MetALD: new opportunities to understand the role of alcohol in steatotic liver disease. Lancet Gastroenterol Hepatol 2023; 8: 866-868
• 9 Åberg F, Byrne CD, Pirola CJ. et al. Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. J Hepatol 2023; 78: 191-206
• 10 Ciardullo S, Carbone M, Invernizzi P. et al. Exploring the landscape of steatotic liver disease in the general US population. Liver Int 2023; 43: 2425-2433
• 11 Mózes FE, Lee JA, Vali Y. et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol 2023; 8: 704-713
• 12 Vali Y, Lee J, Boursier J. et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol 2023; 8: 714-725
• 13 Hardy T, Wonders K, Younes R. et al. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemp Clin Trials 2020; 98: 106175
• 14 Lee BP, Dodge JL, Terrault NA. National prevalence estimates for steatotic liver disease and sub-classifications using consensus nomenclature. Hepatology 2023;
• 15 Hagström H, Vessby J, Ekstedt M. et al. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol 2023;
• 16 Siddiqui MS, Harrison SA, Abdelmalek MF. et al. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology 2018; 67: 2001-2012
• 17 Younossi ZM, Stepanova M, Taub RA. et al. Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. Clin Gastroenterol Hepatol 2022; 20: 1354-1361
• 18 Harrison SA, Taub R, Neff GW. et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 2023; 29: 2919-2928
• 19 Li M, Zhang W, Li X. et al. Metabolic and Risk Profiles of Lean and Non-Lean Hepatic Steatosis among US Adults. Nutrients 2023; 15
• 20 Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther 2017; 46: 85-95